New drug IDE034 targets Hard-to-Treat cancers in early trial

NCT ID NCT07503808

First seen Apr 05, 2026 · Last updated May 08, 2026 · Updated 6 times

Summary

This early-stage study tests a new drug called IDE034 in 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have tumors with specific markers (B7-H3 and PTK7).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • NEXT Texas LLC - Austin

    RECRUITING

    Austin, Texas, 78758, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Texas LLC - Dallas

    RECRUITING

    Irving, Texas, 75039, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Texas LLC - Houston

    RECRUITING

    Houston, Texas, 77054, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Texas LLC - San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Texas LLC - Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.